2. has confirmed HER2-positive expression defined as IHC 2+/ISH+ or IHC 3+
3. was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane
Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
Receives anti-HER2 ADC treatment
Life expectancy \> 3 months
Evidence of measurable or evaluable disease (RECIST 1.1 criteria)in the 28 days before selection
ECOG ≤2
You may not be if
Has uncontrolled or significant cardiovascular disease
Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study
